Deutsch
TU Dresden

search

iPS Cells and Neurodegenerative Disease - Jared Sterneckert

Induced pluripotent stem cell (iPSC) technology offers a unique opportunity to study neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD). Reprogramming enables the generation of iPSC lines directly generated from fibroblasts donated by a patient with an observable phenotype and known genotype. Using iPSCs, theoretically limitless numbers of specialized cells, including neurons, can be generated that carry the same genetic mutations as the donating patient.

Previous and current research

Neurodegenerative diseases like amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD) are becoming more and more common, and very little, if anything can be done to prevent these pathologies from starting or progressing. Therefore, better treatments are urgently needed for these diseases.

Induced pluripotent stem cell (iPSC) technology uniquely enables us to study how ALS and PD occur using patient specific cells. In the past, scientists have had to rely upon animal models or cell lines, which have provided useful insights, but both of these systems can behave differently than patient samples. more

Future projects and goals

  • Generation of iPSC-based models of genetic and sporadic forms of neurodegenerative disease.
  • Phospho-proteomics of iPSC-based models to identify aberrantly regulated signaling pathways causing neurodegeneration.
  • Phenotypic screening of small molecule libraries using iPSC-based models to identify novel drug candidates and disease mechanisms.

Group leader

Selected publications

Lojewski X, Staropoli JF, Biswas-Legrand S, Simas AM, Haliw L, Selig MK, Coppel SH, Goss KA, Petcherski A, Chandrachud U, Sheridan SD, Lucente D, Sims KB, Gusella JF, Sondhi D, Crystal RG, Reinhardt P, Sterneckert J, Schöler H, Haggarty SJ, Storch A, Hermann A, Cotman SL. Human iPSC models of neuronal ceroid lipofuscinosis capture distinct effects of TPP1 and CLN3 mutations on the endocytic pathway. Hum Mol Genet. 2013; 23(8):2005-22.

Dakas PY, Parga JA, Höing S, Schöler HR, Sterneckert J, Kumar K, Waldmann H. Discovery of neuritogenic compound classes inspired by natural products. Angew Chem Int Ed Engl 2013; 52(36): 9576-81.

Reinhardt P, Glatza M, Hemmer K, Tsytsyura Y, Thiel CS, Höing S, Moritz S, Parga JA, Wagner L, Bruder JM, Wu G, Schmid B, Röpke A, Klinguaf J, Schwamborn JC, Gasser T, Schöler HR**, Sterneckert J**. Derivation and Expansion Using Only Small Molecules of Human Neural Progenitors for Neurodegenerative Disease Modeling. PLoS ONE 2013; 8(3): e59252.

Reinhardt P*, Schmid B*, Burbulla LF, Schöndorf DC, Wagner L, Glatza M, Höing S, Hargus G, Heck SA, Dhingra A, Wu G, Müller S, Brockmann K, Kluba T, Maisel M, Krüger R, Berg D, Tsytsyura Y, Thiel CS, Psathaki OE, Klingauf J, Kuhlmann T, Klewin M, Müller H, Gasser T**, Schöler HR**, Sterneckert J. Genetic Correction of a LRRK2 Mutation in Human iPSCs Links Parkinsonian Neurodegeneration to ERK-Dependent Changes in Gene Expression. Cell Stem Cell 2013; 12(3): 354-67.

Höing S, Rudhard Y, Reinhardt P, Stehling M, We G, Peiker C, Böcker A, Glatza M, Slack M, Sterneckert J**, Schöler HR**. Discovery of inhibitors of microglial neurotoxicity acting through multiple mechanisms using a stem cell-based phenotypic assay. Cell Stem Cell 2012; 11(5): 620-632.

Group members

New group members are welcome.
In our lab we are working as a dynamic team to follow our many novel projects. Thus, we are always looking for motivated Master and PhD students or Postdocs to join our endeavor. If you are interested, please send an email to Dr. Jared Sterneckert with a full CV and names of at least two references.

Contact

Group Leader

Jared Sterneckert, PhD
jared.sterneckert[at]crt-dresden.de


Assistant to Group Leader

Daniela Mohrich
daniela.mohrich[at]crt-dresden.de
Phone: +49 (0)351 458 82114